To the content
1 . 2023

Thyroid cancer with toxic goiter

Abstract

Recently, thyroid cancer (TC) has been very often detected in patients operated on for Graves’ disease (GD). There is no clear data on the frequency and risk factors for the development of thyroid cancer in operated patients with GD.

Aim of this study is to assess the risk of developing thyroid cancer in patients with GD after surgical treatment.

Material and methods. The data of 121 patients with GD, after thyreoidectomy at the center of endocrine Surgery in Krasnodar in the period from 2015 to 2020, was evaluated retrospectively. The diagnosis of thyroid cancer was confirmed by the results of a pathoanatomic study. Thyroid cancer was detected after thyroidectomy in 34 patients operated for GD (28.1%). During preoperative ultrasound examination of the thyroid gland (ultrasound), nodular goiter was diagnosed in 62 (51.2%) patients. Nodular formations were not found in other 59 (48.8%) patients with GD.

Results. The frequency of thyroid cancer was significantly higher in patients with nodular formations (38 vs 16%; p=0.009). In 32 of 34 cases, papillary thyroid cancer (PTC) was detected, and in the remaining two cases follicular thyroid cancer. Of the 32 patients with PTC, 28 were of the classical type, and 2 patients had a follicular variant of papillary cancer, 1 – oncocytic and 1 – columnar cell variant of PTC.

Conclusion. Risk of cancer was higher in patients with GD with nodule. In addition to the main examination of patients with GD, ultrasound examination was performed with examination of regional lymph nodes with further determination of surgical tactics.

Keywords:Graves’ disease; thyroid cancer; thyroid node

Funding. The study had no sponsor support.
Conflict of interest. The author declares no conflict of interest.
For citation: Ryabchenko E.V. Thyroid cancer with toxic goiter. Clinical and Experimental Surgery. Petrovsky Journal. 2023; 11 (1): 64–9. DOI: https://doi.org/10.33029/2308-1198-2023-11-1-64-69  (in Russian)

References

1.     Burch H.B., Cooper D.S. Management of Graves’ disease: A review. JAMA. 2015; 314: 2544–54. DOI: https://doi.org/10.1001/jama.2015.16535

2.     Vander J.B., Gaston E.A., Dawber T.R. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968; 69: 537–40. DOI: https://doi.org/10.7326/0003-4819-69-3-537

3.     Pellegriti G., Mannarino C., Russo M., et al. Increased mortality in patients with differentiated thyroid cancer associated with Graves’ disease. J Clin Endocrinol Metab. 2013; 14: 321–5. DOI: https://doi.org/10.1210/jc.2012-2843

4.     Pacini F., Elisei R., Di Coscio G.C., et al. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest. 1988; 11: 107–12. DOI: https://doi.org/10.1007/BF03350115  

5.     Gerenova J., Buysschaert M., de Burbure C.Y., Daumerie C. Prevalence of thyroid cancer in Graves’ disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med. 2003; 14: 321–5. DOI: https://doi.org/10.1016/s0953-6205(03)00105-5

6.     Ozaki O., Ito K., Kobayashi K., Toshima K., Iwasaki H., Yashiro T. Thyroid carcinoma in Graves’ disease. World J Surg. 1990; 14: 437–40. DOI: https://doi.org/10.1007/BF01658550  

7.     Yano Y., Shibuya H., Kitagawa W., et al. Recent outcome of Graves’ disease patients with papillary thyroid cancer. Eur J Endocrinol. 2007; 157: 325–9. DOI: https://doi.org/10.1530/EJE-07-0136  

8.     Tamatea J.A., Tu’akoi K., Conaglen J.V., Elston M.S., Meyer-Rochow G.Y. Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? Aust N Z J Surg. 2014; 84: 231–4. DOI: https://doi.org/10.1111/j.1445-2197.2012.06233.x

9.     Chao T.C., Lin J.D., Chen M.F. Surgical treatment of thyroid cancers with concurrent Graves’ disease. Ann Surg Oncol. 2004; 11: 407–12. DOI: https://doi.org/10.1245/ASO.2004.06.011

10. Weber K.J., Solorzano C.C., Lee J.K., Gaffud M.J., Prinz R.A. Thyroidectomy remains an effective treatment option for Graves’ disease. Am J Surg. 2006; 191: 400–5. DOI: https://doi.org/10.1016/j.amjsurg.2005.10.043

11. Phitayakorn R., McHenry C.R. Incidental thyroid carcinoma in patients with Graves’ disease. Am J Surg. 2008; 195: 292–7. DOI: https://doi.org/10.1016/j.amjsurg.2007.12.006

12. Boutzios G., Vasileiadis I., Zapanti E., et al. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves’ disease. Thyroid. 2014; 24: 347–54. DOI: https://doi.org/10.1089/thy.2013.0133

13. Wei S., Baloch Z.W., LiVolsi V.A. Thyroid carcinoma in patients with Graves’ disease: an institutional experience. Endocr Pathol. 2015; 26: 48–53. DOI: https://doi.org/10.1007/s12022-014-9343-6

14. Gabriele R., Letizia C., Borghese M., et al. Thyroid cancer in patients with hyperthyroidism. Horm Res. 2003; 60: 79–83. DOI: https://doi.org/10.1159/000071875

15. Filetti S., Belfiore A., Amir S.M., et al. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med. 1988; 318: 753–9. DOI: https://doi.org/10.1056/NEJM198803243181206

16. Belfiore A., Russo D., Vigneri R., Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol. 2001; 55: 711–8. DOI: https://doi.org/10.1046/j.1365-2265.2001.01415.x

17. Tam A.A., Kaya C., Kilic F.B., Ersoy R., Cakir B. Thyroid nodules and thyroid cancer in Graves’ disease. Arq Bras Endocrinol Metabol. 2014; 58: 933–8. DOI: https://doi.org/10.1590/0004-2730000003569

18. Ren M., Wu M.C., Shang C.Z., et al. Predictive factors of thyroid cancer in patients with Graves’ disease. World J Surg. 2014; 38: 80–7. DOI: https://doi.org/10.1007/s00268-013-2287-z

19. Staniforth J.U., Erdirimanne S., Eslick G.D. Thyroid carcinoma in Graves’ disease: A meta-analysis. Int J Surg. 2016; 27: 118–25. DOI: https://doi.org/10.1016/j.ijsu.2015.11.027

20. Erbil Y., Barbaros U., Ozbey N., et al. Graves’ disease, with and without nodules, and the risk of thyroid carcinoma. J Laryngol Otol. 2008; 122: 291–5. DOI: https://doi.org/10.1017/S0022215107000448

21. Kaczka K.A., Pomorski L. One-step nucleic acid amplification analysis of sentinel lymph nodes in papillary thyroid cancer patients. Arch Med Sci. 2017; 13: 1416–26. DOI: https://doi.org/10.5114/aoms.2017.65466

22. Hales I.B., McElduff A., Crummer P., et al. Does Graves’ disease or thyrotoxicosis affect the prognosis of thyroid cancer. J Clin Endocrinol Metab. 1992; 75: 886–9. DOI: https://doi.org/10.1210/jcem.75.3.1517381

23. Belfiore A., Garofalo M.R., Giuffrida D., et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab. 1990; 70: 830–5. DOI: https://doi.org/10.1210/jcem-70-4-830

24. Pellegriti G., Belfiore A., Giuffrida D., Lupo L., Vigneri R. Outcome of differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metabol. 1998; 83: 2805–9. DOI: https://doi.org/10.1210/jcem.83.8.4997

25. Ergin A.B., Saralaya S., Olansky L. Incidental papillary thyroid carcinoma: clinical characteristics and prognostic factors among patients with Graves’ disease and euthyroid goiter, Cleveland Clinic experience. Am J Otolaryngol. 2014; 35: 784–90. DOI: https://doi.org/10.1016/j.amjoto.2014.04.013

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Sergey L. Dzemeshkevich
MD, Professor (Moscow, Russia)

Journals of «GEOTAR-Media»